The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.

Inclusion Criteria

• Signed Written Informed Consent
• Subjects must have received at least one dose of Asunaprevir and/or Daclatasvir
• Subjects participating in Daclatasvir and/or Asunaprevir studies (ie, protocol numbers beginning with AI443, AI444 or AI447) may enroll regardless of virologic response
• Completed the required post-treatment follow-up period in previous study
• Must enroll in this study within 6 months of completing previous BMS study or within 6 months of protocol availability at the clinical site
• Men and women, ages 18 and older

Exclusion Criteria:

• Subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis C (CHC) after completion of the previous study during which Asunaprevir and/or Daclatasvir were administered
• Subject must not be participating in any other trial, excluding non-interventional trials
• Prisoners or subjects who are involuntarily incarcerated
• Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness

Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C